DEF 14A: Relay Therapeutics Announces 2024 Annual Meeting of Stockholders

Relay Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 3, 2024, to elect directors, vote on executive compensation, and ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm.

Summary

• Relay Therapeutics has scheduled its 2024 Annual Meeting of Stockholders for June 3, 2024, at 1:30 p.m.
• Eastern Time, as a virtual meeting.
• Stockholders of record as of April 4, 2024, are eligible to vote.
• The meeting will address the election of two Class I directors, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The board of directors recommends voting 'FOR' the election of the director nominees, 'FOR' the advisory vote on executive compensation, and 'FOR' the ratification of the accounting firm appointment.
• Proxy materials are available online, and stockholders can request printed copies.
• Advance registration is required to attend the virtual meeting.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions, reflecting a balanced and professional approach.

Positives

• The board of directors recommends voting 'FOR' all proposals, indicating confidence in the company's direction and management.
• The company is utilizing a 'notice and access' approach for distributing proxy materials, reducing environmental impact and costs.
• Stockholders have the opportunity to provide feedback on executive compensation through an advisory vote.

Future Outlook

The document outlines the agenda and procedures for the upcoming annual meeting, focusing on governance matters and seeking stockholder input on key decisions.

Management Comments

• The board of directors recommends a vote 'FOR' the election of each of the two nominees for class I directors; 'FOR' the approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the accompanying proxy statement; and 'FOR' the ratification of the appointment of our independent registered public accounting firm for the fiscal year ending December 31, 2024.

Industry Context

This announcement is a standard corporate governance procedure for publicly traded companies, ensuring stockholders have the opportunity to participate in key decisions.

Stakeholder Impact

• Shareholders are directly impacted through their voting rights on key company decisions.
• Employees are indirectly impacted through the advisory vote on executive compensation.
• The outcome of the meeting can influence investor confidence and the company's overall performance.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• Interested parties should register in advance to attend the virtual Annual Meeting.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Ernst & Young, Ratification, Virtual Meeting, Relay Therapeutics